Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients
X Wang, M Zeng, X Ju, A Lin, C Zhou… - British Journal of …, 2024 - academic.oup.com
Background Many survivors of a first primary cancer (FPCs) are at risk of developing a
second primary cancer (SPC), with effects on patient prognosis. Primary cancers have …
second primary cancer (SPC), with effects on patient prognosis. Primary cancers have …
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival …
PG Richardson, A Perrot, J San Miguel… - …, 2024 - pmc.ncbi.nlm.nih.gov
The primary and prespecified updated analyses of ICARIA-MM (clinicaltrial gov. Identifier:
NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in …
NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in …
Outcome of second primary malignancies developing in multiple myeloma patients
I Avivi, DH Vesole, J Davila-Valls… - Cancers, 2023 - mdpi.com
Simple Summary The emergence of new therapeutic agents for multiple myeloma (MM) over
the last 2 decades has resulted in a significant improvement in overall survival (OS) …
the last 2 decades has resulted in a significant improvement in overall survival (OS) …
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
JZ Zhang, L Zhang, X Ding, M Wu, DJ Zhang… - European Journal of …, 2025 - Elsevier
ABSTRACT Interferon regulatory factor 4 (IRF4) is specifically overexpressed in multiple
myeloma (MM) and mediates MM progression and survival, making it an emerging target for …
myeloma (MM) and mediates MM progression and survival, making it an emerging target for …
Subsequent malignant neoplasms after primary hematological malignancy in adult patients
RM Rönkkö, AO Nevala, JM Pitkäniemi… - … Journal of Cancer, 2024 - Wiley Online Library
Patients with primary hematological malignancy (HM) are at an elevated risk of subsequent
malignant neoplasms (SMNs), which is a common concern after treatment of primary cancer …
malignant neoplasms (SMNs), which is a common concern after treatment of primary cancer …
[HTML][HTML] Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value
J Du, XR Gu, XX Yu, YJ Cao, J Hou - Blood Science, 2023 - journals.lww.com
Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of
abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant …
abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant …
Thiazolidinedione use is associated with a borderline lower risk of multiple myeloma and a significantly lower risk of death in patients with type 2 diabetes mellitus in …
CH Tseng - Cancers, 2023 - mdpi.com
Simple Summary The effects of thiazolidinedione (TZD) on multiple myeloma have not been
investigated in humans. The reimbursement database of Taiwan's National Health …
investigated in humans. The reimbursement database of Taiwan's National Health …
Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 …
MA Alrasheed, KA Alamer, M Albishi, AA Alsuhibani… - Pharmaceuticals, 2024 - mdpi.com
Background: New multiple myeloma (MM) medications have revolutionized the treatment
landscape, but they are also associated with a range of adverse events (AEs). This study …
landscape, but they are also associated with a range of adverse events (AEs). This study …
Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
CL Jerry Teng, SP Yeh, TY Chen, YC Hung, YC Lin… - …, 2024 - Taylor & Francis
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma
(RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment …
(RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment …
[HTML][HTML] Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study
B Park, E Lee, J Yoon, YJ Park, HS Eom - Cancer Research and Treatment, 2023 - e-crt.org
Purpose This study investigated the incidence of secondary malignancy in multiple myeloma
(MM) patients compared with that in the general population using a population-based …
(MM) patients compared with that in the general population using a population-based …